Smriti Suri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Smriti Suri has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Indu Saxena
2 shared publications- Prasenjit Mitra
Department of Biochemistry, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
2 shared publications - Praveen Sharma
Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Jodhpur, India
2 shared publications - Abhilasha1 shared publication
Abhilasha Abhilasha
Department of Biochemistry , All India Institute of Medical Sciences , Jodhpur , India
1 shared publication- Anshika Chauhan
Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India
1 shared publication
Latest Publications
- Open Access
- 26 October 2026
- Published by Springer Nature in Scientific Reports
Exploring the biomarker potential of LCN2 and MMP9 proteins in Head and Neck Squamous Cell Carcinoma
- 26 October 2026
- Published by Springer Nature in Scientific Reports
Open AccessExploring the biomarker potential of LCN2 and MMP9 proteins in Head and Neck Squamous Cell Carcinoma
- 1 September 2021
- Published by Elsevier in Gene Reports
- Vol. 24
Downregulation of interleukin-10 receptor (IL-10R) along with low serum IL-10 levels in newly diagnosed type 2 diabetes mellitus patients
- 1 September 2021
- Published by Elsevier in Gene Reports
- Vol. 24
Downregulation of interleukin-10 receptor (IL-10R) along with low serum IL-10 levels in newly diagnosed type 2 diabetes mellitus patients
- 15 March 2021
- Published by Walter de Gruyter GmbH in Journal of Basic and Clinical Physiology and Pharmacology
- Vol. 33 (2) , 185-190
Role of interleukin-2 and interleukin-18 in newly diagnosed type 2 diabetes mellitus
Objectives: The study aimed to compare the levels of anti-inflammatory interleukin-2 (IL-2) and proinflammatory interleukin-18 (IL-18) among newly diagnosed type 2 diabetes mellitus (T2DM) and nondiabetic volunteers, to predict their roles as markers in the diagnosis of newly diagnosed T2DM. Methods: In the study, 60 subjects were enrolled (30 T2DM cases and 30 non-diabetic controls). Biochemical parameters such as fasting plasma glucose (FBS), glycated haemoglobin (HbA 1c ), high sensitivity C-reactive protein (hs-CRP) and lipid profile were estimated in auto-analyser. Serum IL-2 and IL-18 levels were assessed by enzyme-linked immune sorbent assay (ELISA). Results: Significant differences were observed in the levels of interleukins among study groups. The median (95% confidence interval) of IL-2 in cases and controls were 8.55 (6.07–47.23) and 45.87 (12.81–145.4) (p=0.02). The median (95% CI) of IL-18 on the other hand in cases and controls were 691.6 (580.3–872.6) and 511.1 (452.6–557.5) (p=0.0014). Conclusions: Our study is the first to correlate IL-2 and IL-18 in newly diagnosed T2DM patients. Findings from this study highlight the anti-inflammatory role of IL-2 and proinflammatory role of IL-18 in T2DM. ROC analysis helped predict their role as markers in T2DM diagnosis.
- 15 March 2021
- Published by Walter de Gruyter GmbH in Journal of Basic and Clinical Physiology and Pharmacology
- Vol. 33 (2) , 185-190
Role of interleukin-2 and interleukin-18 in newly diagnosed type 2 diabetes mellitus
Objectives: The study aimed to compare the levels of anti-inflammatory interleukin-2 (IL-2) and proinflammatory interleukin-18 (IL-18) among newly diagnosed type 2 diabetes mellitus (T2DM) and nondiabetic volunteers, to predict their roles as markers in the diagnosis of newly diagnosed T2DM. Methods: In the study, 60 subjects were enrolled (30 T2DM cases and 30 non-diabetic controls). Biochemical parameters such as fasting plasma glucose (FBS), glycated haemoglobin (HbA 1c ), high sensitivity C-reactive protein (hs-CRP) and lipid profile were estimated in auto-analyser. Serum IL-2 and IL-18 levels were assessed by enzyme-linked immune sorbent assay (ELISA). Results: Significant differences were observed in the levels of interleukins among study groups. The median (95% confidence interval) of IL-2 in cases and controls were 8.55 (6.07–47.23) and 45.87 (12.81–145.4) (p=0.02). The median (95% CI) of IL-18 on the other hand in cases and controls were 691.6 (580.3–872.6) and 511.1 (452.6–557.5) (p=0.0014). Conclusions: Our study is the first to correlate IL-2 and IL-18 in newly diagnosed T2DM patients. Findings from this study highlight the anti-inflammatory role of IL-2 and proinflammatory role of IL-18 in T2DM. ROC analysis helped predict their role as markers in T2DM diagnosis.